Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.

Masahiko AokiHirokazu ShojiKengo NagashimaHiroshi ImazekiTakahiro MiyamotoHidekazu HiranoYoshitaka HonmaSatoru IwasaNatsuko OkitaAtsuo TakashimaKen KatoKazuhide HiguchiNarikazu Boku

Published in: ESMO open (2019)

HPD was observed more frequently after nivolumab compared with irinotecan, which was associated with a poor prognosis after nivolumab but not so clearly after irinotecan.

Keyphrases

poor prognosis
long non coding rna
neoadjuvant chemotherapy
squamous cell carcinoma
combination therapy